WASHINGTON — Steve Ubl, who leads the drug industry lobbying powerhouse PhRMA, has a bold prediction: Democrats might control the House, Senate, and White House, but Covid-19 has given pharma the advantage in the debate over drug pricing.
It’s bold because there is not a single House Democrat who voted against H.R. 3, the ambitious Democratic drug pricing bill that the pharmaceutical industry detests.
About the Author Reprints
